Tenax Therapeutics, Inc.
TENX· Nasdaq
TENXTenax Therapeutics, Inc.
Filed Aug 16, 2021 · 10-Q · 47 days after period end · 0001654954-21-009088
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Net Income | -$1.72M | -$2.15M | $1.76M | $1.87M |
| EPS Diluted | -$0.10 | -$0.23 | -$0.28 | -$1.28 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end
